Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease The September 10, 2024, article by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results